Aimspro info
Posted: Fri Oct 15, 2004 6:54 am
Article at www.proventus.org.uk
Find out the latest news from the Scientists, 15/10/2004
Dr Bryan Youl, the consultant neurophysiologist leading the clinical research programme for Daval, has provided us with some important news. He is delighted to report that the observations already made in the central nervous system (in Multiple Sclerosis patients) are being echoed by similar findings in peripheral nerves (outside the brain and spine). This is an exciting development.
He is also encouraged by the increasing interest in Aimspro shown by growing numbers of specialist colleagues. The breadth of experience now being amassed is leading to greater certainty about the novel mechanisms of action of the medication and expanding the possibilities for its use.
Note: Don't forget to sign the petition on the site if you have not already.
All this helps in the eventual application for licensing of the Daval product, the goal we all have in mind.
Find out the latest news from the Scientists, 15/10/2004
Dr Bryan Youl, the consultant neurophysiologist leading the clinical research programme for Daval, has provided us with some important news. He is delighted to report that the observations already made in the central nervous system (in Multiple Sclerosis patients) are being echoed by similar findings in peripheral nerves (outside the brain and spine). This is an exciting development.
He is also encouraged by the increasing interest in Aimspro shown by growing numbers of specialist colleagues. The breadth of experience now being amassed is leading to greater certainty about the novel mechanisms of action of the medication and expanding the possibilities for its use.
Note: Don't forget to sign the petition on the site if you have not already.
All this helps in the eventual application for licensing of the Daval product, the goal we all have in mind.
Great, thanks for posting this.